comparemela.com

Latest Breaking News On - நியால் டோநிலீ - Page 1 : comparemela.com

Cosmo Pharmaceuticals Announces Cassiopea SpA s Signing of License and Supply Agreements for Winlevi® in US and Canada

Search jobs 26-Jul-2021 Cosmo Pharmaceuticals Announces Cassiopea SpA’s Signing of License and Supply Agreements for Winlevi® in US and Canada Cosmo Pharmaceuticals N.V. / Key word(s): Agreement/Alliance 26-Jul-2021 / 06:01 GMT/BST Release of an ad hoc announcement pursuant to Art. 53 LR The issuer is solely responsible for the content of this announcement. Ad hoc announcement pursuant to Art. 53 LR Dublin, Ireland - 26 July 2021: Cosmo Pharmaceuticals N.V. (SIX: COPN, XETRA: C43) announced today that Cassiopea SpA (SIX: SKIN), a company in which it holds 46.56% of the ordinary shares, has signed license and supply agreements with Sun Pharmaceutical Industries Ltd. (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715, Sun Pharma ) for Winlevi

Dundalk Chamber to host a free Family Succession and Tax Planning Webinar

Cosmo announces the start of trading of its shares on XETRA

Cosmo announces the start of trading of its shares on XETRA Search jobs Cosmo Pharmaceuticals N.V. / Key word(s): Miscellaneous 19-Apr-2021 / 06:00 GMT/BST Release of an ad hoc announcement pursuant to Art. 53 KR The issuer is solely responsible for the content of this announcement. Dublin, Ireland - 19 April 2021: Shares of Cosmo Pharmaceuticals NV ( Cosmo ) (SIX: COPN), which have traded on the Swiss Stock Exchange since 2007, will now also trade on XETRA in Frankfurt, Germany. Trading will commence today, Monday, at 9:00am CEST under tickersymbol C43. COSMO PHARMACEUT. EO-,26 ISIN: NL0011832936 | WKN: A2AJ68 | Ric: C43 | Type: Equity. The listing on XETRA, Germany s most important stock exchange, is aimed at providing easier access to European investors, significantly improving the visibility of the Company on the capital markets and increasing the overall liquidity in the trading of Cosmo s shares. 

Cosmo announces FDA approval of GI Genius intelligent endoscopy module, its revolutionary Artificial Intelligence device for lesion detection during colonoscopy

(1) DUBLIN, April 12, 2021 /PRNewswire/ Cosmo Pharmaceuticals NV (SIX: COPN) today announced the FDA approval of GI Genius intelligent endoscopy system, its revolutionary device for lesion detection during colonoscopy. The GI Genius module FDA approval marks a pivotal milestone for Cosmo after more than 10 years of research and investments focused to generate disruptive innovations in the field of colon s disease and optimization of the colonoscopy procedure. The development of GI Genius intelligent endoscopy module has been possible thanks to the leadership position of Cosmo, its unique proprietary library of high-definition loss-less videos of colonoscopies and its proprietary software and algorithms. The device is the first of its kind to obtain the FDA approval through the De Novo application. The device operates in real time to assist the endoscopist in the detection of lesions, is very simple to use and is compatible with all endoscopes. Cosmo is the sole manufacturer. Medt

Cosmo Full-Year Report 2020: Cosmo returns to operating profit

Cosmo Full-Year Report 2020: Cosmo returns to operating profit
prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.